| Followers | 0 |
| Posts | 3251 |
| Boards Moderated | 0 |
| Alias Born | 04/21/2025 |
Friday, August 29, 2025 8:24:45 AM
Thanks captain obvious.😂
However, with no DCVax approval (with NICE reimbursement), they will have lost a big future revenue source. Because Advent is private, we have no idea of accurate sales figures, clients, profits, or debt. As a subsidiary of NWBO, they will now also carry the burden of NWBO losses, expenses and debt as well as their own.
I smell a reverse split and much more dilution ahead. Even if an approval was granted, they still have to run ped. trials, and hope for NICE reimbursement (which is highly unlikely bc of the cost). Also, a sales and marketing team is necessary and the launch will take many months. NICE will not give out an extra $150K (on top of SOC costs) for a vaccine that is obviously questionable, at best - based on peer reviews and the very long MHRA process.
It's fun to watch this reality show in real time, and I am glad I am not invested, which also makes me more objective. Nothing worse than being emotionally attached to a stock, it clouds your thinking.
GL
However, with no DCVax approval (with NICE reimbursement), they will have lost a big future revenue source. Because Advent is private, we have no idea of accurate sales figures, clients, profits, or debt. As a subsidiary of NWBO, they will now also carry the burden of NWBO losses, expenses and debt as well as their own.
I smell a reverse split and much more dilution ahead. Even if an approval was granted, they still have to run ped. trials, and hope for NICE reimbursement (which is highly unlikely bc of the cost). Also, a sales and marketing team is necessary and the launch will take many months. NICE will not give out an extra $150K (on top of SOC costs) for a vaccine that is obviously questionable, at best - based on peer reviews and the very long MHRA process.
It's fun to watch this reality show in real time, and I am glad I am not invested, which also makes me more objective. Nothing worse than being emotionally attached to a stock, it clouds your thinking.
GL
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
